Stocks · News reference
Ultragenyx shares rise after FDA approval of Genglycos, with a $2.7 million wholesale cost and $362 million peak sales estimate.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $75 to $80.
Read original at benzingaMorgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $67 to $74.
Read original at benzingaCanaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $81 to $83.
Read original at benzingaCitigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $45 to $58.
Read original at benzinga